AFT Pharmaceuticals Opens Combogesic to U.S. Healthcare Organizations via Cost Plus Marketplace

AFT Pharmaceuticals said on October 29, 2026 that COMBOGESIC (acetaminophen 325 mg/ibuprofen 97.5 mg) tablets are now available for purchase by registered healthcare organizations through Mark Cuban Cost Plus Marketplace. The New Zealand-based company announced the channel in a PR Newswire release.

How the Cost Plus Marketplace Channel Works

Mark Cuban Cost Plus Drug Company operates the marketplace, where pharmacies, hospitals, clinics and other eligible organizations can order COMBOGESIC through their accounts. The listing follows the partnership the two companies announced in September, when AFT Pharmaceuticals said it would bring the prescription non-opioid to the U.S. with the marketplace.

COMBOGESIC is a prescription-only fixed-dose combination of acetaminophen and ibuprofen, indicated in adults for short-term management of mild to moderate acute pain. Under the FDA-approved regimen, patients may take three tablets every six hours as needed, up to 12 tablets in 24 hours, for a maximum daily dose of 3,900 mg acetaminophen and 1,170 mg ibuprofen. AFT manufactures the tablets with its patented QikSolv formulation technology, a proprietary micronization process exclusive to the U.S. market.

In a Phase 3 study of 408 adults with moderate-to-severe pain following dental surgery, 23.9% of patients receiving COMBOGESIC required opioid rescue medication, compared with 43.2% on ibuprofen alone and 53.2% on acetaminophen alone. The drug provided 78% more effective pain relief than acetaminophen alone and 36% more than ibuprofen alone, both P<0.001, with tolerability comparable to either component.

"People often assume a combination like this is just two familiar pills in one. The data show it's more than that," said Dr. Hartley Atkinson, founder and managing director of AFT Pharmaceuticals. "Fewer patients on COMBOGESIC needed opioid rescue medication than those taking either ingredient on its own. Through the Marketplace, healthcare organizations across the U.S. can now give their clinicians that option."

Mark Cuban, founder of Mark Cuban Cost Plus Drug Company, said: "We should all get excited to have more prescription non-opioid options to combat pain." He added that the partnership pairs new medications with access and price transparency.

Cost Plus Drug Company's Recent Partnerships

According to akta.pro company records, Mark Cuban Cost Plus Drug Company integrated into the TrumpRx federal prescription drug portal in May 2026, supplying 559 generic medications. In April 2026, the company partnered with the Bristol Myers Squibb and Pfizer Alliance to offer branded Eliquis at $345 per 30-day supply for cash-paying patients, the first major brand-name drug on CostPlusDrugs.com. The same records list a deepened partnership with Humana's CenterWell Pharmacy in April 2026 to develop employer prescription solutions.

Earlier Steps Toward the Combogesic Listing

AFT Pharmaceuticals announced the U.S. launch of Combogesic, a prescription-strength combination of acetaminophen and ibuprofen for mild-to-moderate acute pain, in partnership with Mark Cuban Cost Plus Marketplace in September 2026, according to PR Newswire. In May 2026, Cost Plus Drug Company was integrated into Elevance Health's Cost Plus Marketplace for businesses as Elevance expanded access for employer groups and health plan members, akta.pro records show. In June 2026, the company was integrated into SmithRx's partner ecosystem for GLP-1 employer programs, the same records state.

Where Combogesic Is Available

COMBOGESIC is already available in 67 countries worldwide, and AFT directs U.S. patients and clinicians to Combogesic.com for information.